drugset / Trial / NCT01343394
Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
Phase 1
Withdrawn
Aryn Knight
Baylor College of Medicine · collabCord Blood Registry, Inc. · collabFlorida Hospital for Children · collabM.D. Anderson Cancer Center · collabThe Methodist Hospital Research Institute · collabThe University of Texas Health Science Center, Houston · collab
NaSingle-groupOpen-labelTreatment
Summary
The objectives of this study are: 1. To see if autologous human umbilical cord blood treatment is safe for children with acquired hearing loss, and 2. To determine if late functional outcome is improved following autologous human umbilical cord blood treatment for children with acquired hearing loss.
Timeline
- Start
- 2011-04
- Primary completion
- 2013-01
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous cord blood | Cell therapy | 6 cells/kg | Intravenous |